141 results on '"Malatestinic, William N."'
Search Results
2. Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
3. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
4. Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab
5. Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
6. Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
7. Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
8. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases
9. Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry
10. Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis
11. Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data
12. Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry
13. Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
14. Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry.
15. Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data.
16. 41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials
17. Factors Associated with Treatment Escalation for Psoriasis: an Electronic Health Record Platform for Retrospective and Prospective Real-world Studies
18. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs
19. US health care utilization and costs in adult patients with atopic dermatitis by disease severity
20. Treatment Satisfaction and Decision‐making from the Patient Perspective in Axial Spondyloarthritis: Real‐World Data from a Descriptive Cross‐sectional Survey Study from the ArthritisPower Registry
21. Inadequate response and treatment patterns in adults diagnosed with atopic dermatitis and treated with topical therapy
22. 52244 Early Improvement in Nail and Scalp Psoriasis from a Prospective Observational Study of Patients with Psoriasis in Special Areas (PSoSA) Initiating Ixekizumab: Results from the First Interim Analysis.
23. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice
24. Inadequate response and treatment patterns in adults diagnosed with atopic dermatitis and treated with topical therapy.
25. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases.
26. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice.
27. The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study.
28. Disease response and patient-reported outcomes among initiators of ixekizumab.
29. The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study
30. Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
31. Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry
32. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
33. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
34. Disease response and patient-reported outcomes among initiators of ixekizumab
35. Clinical and Quality of Life Outcomes Among Ixekizumab -Treated Psoriasis Patients in a Real-World Setting: Results from a Single US Dermatology Referral Practice
36. Treatment Satisfaction and Decision‐making from the Patient Perspective in Axial Spondyloarthritis: Real‐World Data from a Descriptive Cross‐sectional Survey Study from the ArthritisPower Registry.
37. Evaluation of Changes in Skin and Joint Outcomes and Associated Treatment Changes in Psoriatic Arthritis (PsA): Experience From the Corrona PsA/SpA Registry
38. Su1967 DISEASE BURDEN AND PATIENT-REPORTED OUTCOME MEASURES AMONG ULCERATIVE COLITIS PATIENTS ACCORDING TO THERAPY AT ENROLLMENT INTO THE CORRONA IBD REGISTRY
39. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab
40. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
41. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab
42. Evaluating the clinical and financial impact of severe sepsis with Medicare or other administrative hospital data
43. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry
44. Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study
45. Evaluation of Changes in Skin and Joint Outcomes and Associated Treatment Changes in Psoriatic Arthritis (PsA): Experience From the Corrona PsA/SpA Registry.
46. Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry
47. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis
48. Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study.
49. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review.
50. Is a Paradigm Shift in US Healthcare Reimbursement Inevitable?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.